Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-01
2005-11-01
Shameem, Golam M M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S139000, C544S370000, C514S254050, C514S231200
Reexamination Certificate
active
06960582
ABSTRACT:
Compounds having the general structure II are provided:A is selected from the group consisting of C or CH and X and Y are independently selected from the group consisting of CH2, N, C═O, C═S, (CR6R7)n, S═O, SO2, O, NR9, S, C(═O)—(CR6R7)n, and C(═S)—(CR6R7)nwhere n is 1, 2, or 3. W is selected from the group consisting ofand Z1, Z2, and Z3are independently selected from the group consisting of substituted carbon and nitrogen. L is selected from the group consisting of N, O, S, S═O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Compounds of formula II are agonists of the melanocortin-4 receptor (“MC4-R”) and therefore may have useful properties for controlling diseases related to MC4-R action in humans, such as obesity and type II diabetes.
REFERENCES:
patent: 4732916 (1988-03-01), Satoh et al.
patent: 4824835 (1989-04-01), Mertens et al.
patent: 4874864 (1989-10-01), Schnur et al.
patent: 4948891 (1990-08-01), Schnur et al.
patent: 4948901 (1990-08-01), Schnur et al.
patent: 5086057 (1992-02-01), Sasagawa
patent: 5124328 (1992-06-01), Fisher et al.
patent: 5352704 (1994-10-01), Okuyama et al.
patent: 5362902 (1994-11-01), Barnish et al.
patent: 5547966 (1996-08-01), Atwal et al.
patent: 5637439 (1997-06-01), Kaneko et al.
patent: 5731408 (1998-03-01), Hadley et al.
patent: 5750573 (1998-05-01), Bianchi et al.
patent: 5885985 (1999-03-01), Macdonald et al.
patent: 5889025 (1999-03-01), Lohray et al.
patent: 5952381 (1999-09-01), Chen et al.
patent: 5962530 (1999-10-01), Engel et al.
patent: 6020349 (2000-02-01), Ankersen et al.
patent: 6030985 (2000-02-01), Gentile et al.
patent: 6054556 (2000-04-01), Huby et al.
patent: 6060589 (2000-05-01), Stark et al.
patent: 6127343 (2000-10-01), Ankersen et al.
patent: 6225331 (2001-05-01), Cupps et al.
patent: 6297233 (2001-10-01), Stein et al.
patent: 6391878 (2002-05-01), Cupps et al.
patent: 6638927 (2003-10-01), Renhowe et al.
patent: 6716840 (2004-04-01), Chu et al.
patent: 0343894 (1989-11-01), None
patent: 0354553 (1990-02-01), None
patent: WO 96/04270 (1996-02-01), None
patent: WO 96/24580 (1996-08-01), None
patent: WO 97/19911 (1997-06-01), None
patent: WO 97/41119 (1997-11-01), None
patent: WO 98/07420 (1998-02-01), None
patent: WO 99/64002 (1999-12-01), None
patent: WO 00/03973 (2000-01-01), None
patent: WO 00/17191 (2000-03-01), None
patent: WO 00/74679 (2000-12-01), None
patent: WO 01/10842 (2001-02-01), None
patent: WO 01/55106 (2001-08-01), None
patent: WO 01/55107 (2001-08-01), None
patent: WO 01/55109 (2001-08-01), None
patent: WO 01/70337 (2001-09-01), None
patent: WO 01/70708 (2001-09-01), None
patent: WO 02/062776 (2002-08-01), None
patent: WO 03/099818 (2003-12-01), None
Cupps et al (1998): STN International, CAPLUS database, Columbus (Ohio), Accession No. 1998: 388504.
K. G. Mountjoy et al., “The Cloning of a Family of Genes that Encode the Melanocortin Receptors,”Science, 1992, vol. 257, pp. 1248-1251.
D. Huszar et al., “Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice,”Cell, 1997, vol. 88, pp. 131-141: Cell Press.
M. E. Hadley et al., “The Proopiomelanocortin System,”Annals New York Academy of Sciences, 1999, vol. 885, pp. 1-21.
L. L. Klefer et al., “Mutations in the Carboxyl Terminus of the Agouti Protein Decrease Agouti Inhibition of Ligand Binding to the Melanocortin Receptors,”Biochemistry, 1997, vol. 36, pp. 2084-2090; American Chemical Society.
D. Lu et al., “Agouti Protein is an Antagonist of the Melanocyte-Stimulating-Hormone Receptor,”Nature, 1994, vol. 371,pp. 799-802.
T. M. Fong et al., “ART (Protein Product of Agouti-Related Transcript as an Antagonist of MC-3 and MC-4 Receptors,”Biochemical and Biophysical Research Communications, 1997. vol. 237, pp. 629-631: Academic Press.
M. Rossi et al., “A C-Terminal Fragment of Agouti-Related Protein Increases Feeding and Antagonizes the Effect of Alpha-Melanocyte Stimulating Homone in Vivo,”Endocrinology, 1998, vol. 139, No. 10, pp. 4428-4431.
J. March,Advanced Organic Chemistry—Reactions, Mechanisms and Structure, 3rd ed., 1985, John Wiley & Sons, Inc., New York.
F. A. Carey et al.,Advanced Organic Chemistry—Reactions, Mechanisms and Structure, 1985; John Wiley & Sons, Inc., New York.
B.S. Fumiss et al.,Vogel's Textbook of Practical Organic Chemistry, 5thed., 1990; Plenum Press, New York.
T.W. Greene,Protective Groups in Organic Synthesis, 1sted., 1981; Longman ScientiToc & Technical and John Wiley & Sons, Inc., New York.
R. C. Larock,Comprehensive Organic Transformations—A Guide to Functional Group Preparations, 1989; VCH Publisher's Inc., New York.
I. Bell et al., “Efficient Synthesis of 1-Heterocyclic-3-Aminopyrrolidinones,”Tetrahedron Letters, 2000, pp. 1141-1145; Elsevier Science, Ltd.
XP-001064218, M. Julia et al., “Amidines et Guanidines Apparentées {dot over (a)} la Congocidine,”Bulletin de la Société Chemique de France, 1968, No. 1, pp. 376-382.
J. J. Sims et al., “6-Methoxy-β-Tetralone,”Organic Synthesis, vol. 51, pp. 109-113.
D. M. Tschaen et al., “Asymmetric Synthesis of MK-0499,”J. Org. Chem., 1995, vol. 60, pp. 4324-4330; American Chemical Society.
J. B. Nevy et al., “Transition State Imbalance in the Deprotonation of Substituted 2-Tetralones by Hydroxide Ion,”J. Am. Chem. Soc., 1997, vol. 119, pp. 12722-12726; American Chemical Society.
D. A. Quagliato et al., “Efficient Procedure for the Reduction of α-Methylamines,”J. Org. Chem., 2000, vol. 65, pp. 5037-5042; American Chemical Society.
J. W. Mickelson et al., “Asymmetric Synthesis of 2,6-Methylated Piperazines,”J. Org. Chem., 1995, vol. 60, pp. 4177-4183; American Chemical Society.
H. C. Brown et al., “Organoboranes for Synthesis. 7. An Improved General systhesis of Primary Amines From Alkenes via Hydroboration-Organoborane Chemistry,”Tetrahedron, 1987, vol. 43, No. 18, pp. 4071-4078; Pergamon Journals Ltd.
S. Bhattacharyya et al., “Selective Monoalkylation of Ammonia: A High Throughput Synthesis of Primary Amines,”Synlett, 1999, No. 11, pp. 1781-1783: Thieme Stuttgart, New York.
J. Alexander et al., “(Acyloxy)alkyl Carbamates as Novel Bioreversible Prodrugs for Amines: Increased Permeation through Biological Membranes,”J. Med. Chem., 1988, vol. 31, pp. 318-322; American Chemical Society.
J. Weinstock et al., “Synthesis and Evaluation of Non-Catechol D-1 and D-2 Dopamine Receptor Agonists: Benzimidazol-2-one, Benzoxazol-2-one, and the Highly Potent Benzothiazol-2-one 7-Ethylamines,”J. Med. Chem., 1987, vol. 30, pp. 1166-1176; American Chemical Society.
Website: http://www.idealibrary.com/links/doi/10.1006/bbrc.1997., Abstract-T. M. Fong et al., “ART (Protein Product of Agouti-Related Transcript) as an Antagonist of MC-3 and MC-4 Receptors,”Biochemical and Biophysical Research Communications, Aug. 28, 1997, vol. 237, No. 3.
Website: wysiwyg://36/http://www.sciencemag.org/. . . ar=2001&hits=10&sendit.x=36&sendit.y, M. M. Ollman et al., “Antagonism of Central Melanocortin Receptors in Vitro and in Vivo by Agouti-Related Protein,”Science, 1997, vol. 276, pp. 135-138.
M. M. Ollman et al., “Antagonism of Central Melanocortin Receptors in Vitro and in Vivo by Agouti-Related Protein,”Science, Oct. 3, 1997, vol. 278, pp. 135-138.
Wolff, M. E., “Burger's Medicinal Chemistry and Drug Discovery 5thEdition,” pp. 975-977 (1995), M. E. Wolff (ed.); published by John Wiley & Sons (New York, NY).
Banker, G. S. et al., “Modern Pharmaceutics, 3rdEdition,” pp. 596 and 451 (1996), G. S. Banker and C. T. Rhodes (eds.); published by Marcel Dekker, Inc. (New York, NY).
West, A. R., “Solid State Chemistry and Its Applications, ” pp. 358 and 365 (1988), A. R. West (ed.); pu
Boyce Rustum
Duhl David
Chiron Corporation
Collier Steven W.
Friedrichsen Bernard P.
Harbin Alisa A.
Shameem Golam M M
LandOfFree
Guanidino compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Guanidino compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Guanidino compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3463106